A number of therapeutic approaches are anticipated which may avoid activating latently infected CD4+ T cells and cells of the monocytic lineage which would increase HIV-1 replication and shedding, and potential de novo infection of CD4+ cells within host, as well as increasing risk of transmission to a new host (Richman et al., 2009; Deeks et al., 2012). This evidence concerns the gene CD4 and infection.